Table 4.
Biodegradable polymer wafers for the treatment of brain tumors
| Biodegradable polymers | Polymer type | Drug | Status | Clinical Use | Clinical Trial | Outcomes |
|---|---|---|---|---|---|---|
| 150-190nm | PLGA wafer | 5-fluorouracil | Investigational compound in pre-clinical studies | Not yet reported | ||
| Gliadel® wafer | Carmustine with 5-ALA followed by RT and TMZ | Phase II (completed) | Primary GBM | NCT01310868 | Gliadel® and 5-ALA increased cerebrospinal fluid leaks, intracranial hypertension, no survival data published | |
| Gliadel® wafer | carmustine | Phase II (recruiting) | Metastatic brain tumor | NCT04222062 | Not yet reported | |
| Gliadel® wafer | Carmustine and systemic O6-benzylguanine | Phase II (completed) | Recurrent GBM | NCT00362921 | Significant improvement in OS with increase in adverse events of hydrocephalus, CSF leak and CSF/brain infection 180. | |
| Cerebraca wafer | (Z)-n-butylidenephthalide ((Z)-BP; and Carboxyphenoxypropane-Sebacic Acid Copolymer with adjuvant TMZ | Cerebraca wafer (Phase I & IIa) (recruiting) | Recurrent HGG | NCT03234595 | Not yet reported |
Abbreviations: PLGA: PEGylated-poly (L-lactic co-glycolic acid); GBM: glioblastoma; TMZ: temozolomide; HGG: high-grade glioma; CSF: cerebrospinal fluid; 5-ALA: 5-aminolevulinic acid.